CXCL9 and −10 have also been reported to attract tumor-infiltrating lymphocytes and immunological infiltrates, positively linked with better clinical outcomes in human serous ovarian cancer [95, 97–99]. This evidence concerns the gene CXCL9 and neoplasm.